A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.

Journal of clinical pharmacology

Volumn 50, Issue 9, 2010, Pages 1031-1038

  Zhang, Xiaoping ^a   Huang, Yue ^b   Navarro, Mercidita T ^b   Hisoire, Grace ^b   Caulfield, John P ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PAMAPIMOD; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG INTERACTION; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDONES; PYRIMIDINES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 77956566269     PISSN: None     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009357433     Document Type: Article

References (0)